FDA Approves New Treatment for Hemophilia
The U.S. Food and Drug Administration (FDA) approved BAY94-9027, or antihemophilic factor (recombinant), PEGylated-aucl, for the prophylactic treatment of adults and adolescents (≥12 years)...
FDA Approves Ibrutinib Combo for Waldenström Macroglobulinemia
The U.S. Food and Drug Administration (FDA) approved ibrutinib, in combination with rituximab, for the treatment of adult patients with Waldenström macroglobulinemia (WM). In...
Elephants’ “Zombie Gene” May Prevent Cancer
Researchers have identified a gene that appears to solve the mystery of why elephants – who should be at a greater risk of developing...
Oncology Community Reacts to Medicare Advantage’s “Step Therapy” Decision
In early August 2018, the Centers for Medicare and Medicaid Services (CMS) announced it will allow Medicare Advantage plans to implement “step therapy” for...
Theranos Shutting Down Amid Fraud Allegations
In a letter to investors, the CEO of Theranos announced that the bloodtesting company is preparing to shut down. Theranos has faced a U.S....
FDA Warns Against Using Azithromycin After Stem Cell Transplant
The U.S. Food and Drug Administration (FDA) issued a statement advising clinicians to avoid using the antibiotic azithromycin in patients with certain cancers who...
FDA Approves Mogamulizumab-kpkc for Two Types of Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) approved mogamulizumab-kpkc for intravenous use in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome...
New Immunotherapy Approach Shows Activity in NCI Trials
Treatment with tumor-infiltrating lymphocytes (TILs), a new type of immunotherapy, induced complete remission in a patient with breast cancer, according to a report by...
Lusutrombopag Approved for Thrombocytopenia in Chronic Liver Disease
The U.S. Food and Drug Administration has approved lusutrombopag for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to...
FDA Approves Second Filgrastim Biosimilar
Filgrastim-aafil received approval from the U.S. Food and Drug Administration (FDA), making it the second approved biosimilar version of filgrastim. The treatment was given...
Current Issue
November 2018, Volume 4, Issue 13
This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.
